Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The GTP-bound Ras protein is the **active form** of Ras, a small GTPase acting as a molecular switch in intracellular signaling. When bound to GTP, **Ras undergoes conformational changes in the switch I and II regions, enabling it to interact with downstream effector proteins (such as Raf kinase, PI3K, and Ral-GDS), thereby propagating proliferative and survival signals**[1][2][4][5][6]. The three main human isoforms—HRAS, KRAS, and NRAS—cycle between an inactive GDP-bound state and an active GTP-bound state; this cycle is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs)[1][2][5][6]. Dysregulation or mutation (particularly leading to constitutively GTP-bound, active signaling) is a **major driver of oncogenesis in many cancers**[1][2][6]. Selective inhibition of mutant GTP-bound KRAS proteins is an area of intense drug development, with clinical inhibitors now approved for certain KRAS mutations.
Covalent inhibition of mutant GTP-bound KRAS (e.g., G12C) blocks downstream signaling Disruption of RAS-effector interface (investigational)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras homolog enriched in brain (Ras protein, GTP-bound state) (RAS (GTP-bound)).